Intriguingly, some studies suggest that BCL-XL may be more potent at rendering resistance since BIM preferred interacting with BCL-XL rather than MCL1 in venetoclax-treated CLL cells [58]. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.